Nitric oxide does not mediate but inhibits transformation and tumor phenotype.

UNLABELLED Although inducible nitric oxide synthase (iNOS) and nitric oxide (NO) are implicated in tumor pathology, their role in the early stages of carcinogenesis is not well defined. Tumor necrosis factor alpha (TNFalpha) induces iNOS and NO production in transformation-sensitive JB6 P+, but not in transformation-resistant JB6 P-, mouse epidermal cells. We tested the hypothesis that iNOS, by generating NO and reactive nitrogen species, mediates tumor promoter-induced transformation. Specific [N-[3-(aminomethyl)benzyl]acetamidine (1400W)] and non-specific (N(omega)-methyl-L-arginine) iNOS inhibitors significantly reduced TNFalpha-induced NO production in P+ cells but both iNOS inhibitors enhanced TNFalpha-induced anchorage-independent transformation, thus ruling out a mediator role and suggesting an inhibitor role for NO. Independent support for an inhibitor role came from the observation that the NO donor [(Z)-1-[N-(2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate (DETA/NO)] inhibited TNFalpha- and 12-O-tetradecanoylphorbol-13-acetate-induced transformation. DETA/NO treatment also suppressed tumor phenotype in tumorigenic JB6 RT101 (Tx) cells. Higher concentrations of DETA/NO induced apoptosis. The transformation inhibitory effect of lower DETA/NO concentrations may be attributable in part to inhibition by NO of NF-kappaB-dependent but not of AP-1-dependent transcription. IN CONCLUSION (a) induction of iNOS and NO production does not mediate but actually prevents tumor promotion; (b) iNOS inhibitors enhance the transformation response, and therefore appear not to be appropriate as chemoprevention agents; and (c) NO has both chemopreventive and tumoricidal effects, suggesting promise in cancer chemoprevention and therapy.

[1]  C. Harris,et al.  Nitric oxide in cancer and chemoprevention. , 2003, Free radical biology & medicine.

[2]  N. Colburn,et al.  The role of AP-1, NF-кB and ROS/ NOS in skin carcinogenesis: The JB6 model is predictive , 2002 .

[3]  N. Colburn,et al.  Transactivation of Fra-1 and Consequent Activation of AP-1 Occur Extracellular Signal-Regulated Kinase Dependently , 2002, Molecular and Cellular Biology.

[4]  H. Ohshima,et al.  Suppression of intestinal polyposis in Apc(Min/+) mice by inhibiting nitric oxide production. , 2001, Cancer research.

[5]  M. Morohashi,et al.  Immunohistochemical study of inducible nitric oxide synthase in skin cancers , 2001, Journal of cutaneous pathology.

[6]  R. Poulsom,et al.  Lack of inducible nitric oxide synthase promotes intestinal tumorigenesis in the Apc(Min/+) mouse. , 2001, Gastroenterology.

[7]  Santiago Lamas,et al.  Nitrosylation The Prototypic Redox-Based Signaling Mechanism , 2001, Cell.

[8]  D. S. St. Clair,et al.  Overexpression of manganese superoxide dismutase suppresses tumor formation by modulation of activator protein-1 signaling in a multistage skin carcinogenesis model. , 2001, Cancer research.

[9]  C. Suschek,et al.  Inducible nitric oxide synthase-derived nitric oxide in gene regulation, cell death and cell survival. , 2001, International immunopharmacology.

[10]  P. Trikha,et al.  Nitroglycerin: a NO donor inhibits TPA-mediated tumor promotion in murine skin. , 2001, Carcinogenesis.

[11]  L. Magnelli,et al.  Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions , 2001, The Journal of pathology.

[12]  N. Colburn,et al.  Transformation nonresponsive cells owe their resistance to lack of p65/nuclear factor-kappaB activation. , 2001, Cancer research.

[13]  C. Colton,et al.  Mechanisms of the antioxidant effects of nitric oxide. , 2001, Antioxidants & redox signaling.

[14]  P K Lala,et al.  Role of nitric oxide in carcinogenesis and tumour progression. , 2001, The Lancet. Oncology.

[15]  H. E. Marshall,et al.  Inhibition of NF-kappa B by S-nitrosylation. , 2001, Biochemistry.

[16]  A. Murakami,et al.  Nitric oxide synthase is induced in tumor promoter-sensitive, but not tumor promoter-resistant, JB6 mouse epidermal cells cocultured with interferon-gamma-stimulated RAW 264.7 cells: the role of tumor necrosis factor-alpha. , 2000, Cancer research.

[17]  H. E. Marshall,et al.  Nitrosation and oxidation in the regulation of gene expression , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  N. Tretyakova,et al.  Peroxynitrite-induced DNA damage in the supF gene: correlation with the mutational spectrum. , 2000, Mutation research.

[19]  P. Hainaut,et al.  Nitric oxide nitrates tyrosine residues of tumor-suppressor p53 protein in MCF-7 cells. , 2000, Biochemical and biophysical research communications.

[20]  G. Kollias,et al.  Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis , 1999, Nature Medicine.

[21]  S. Meltzer,et al.  Increased expression and cellular localization of inducible nitric oxide synthase and cyclooxygenase 2 in Helicobacter pylori gastritis. , 1999, Gastroenterology.

[22]  W P Bennett,et al.  Relationship between p53 mutations and inducible nitric oxide synthase expression in human colorectal cancer. , 1999, Journal of the National Cancer Institute.

[23]  Z. Dong,et al.  Expression of dominant negative Erk2 inhibits AP-1 transactivation and neoplastic transformation , 1998, Oncogene.

[24]  D. Wink,et al.  Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. , 1998, Free radical biology & medicine.

[25]  H. Kuo,et al.  Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. , 1998, British Journal of Cancer.

[26]  J. Moss,et al.  Analysis of the cytokine-stimulated human inducible nitric oxide synthase (iNOS) gene: characterization of differences between human and mouse iNOS promoters. , 1998, Biochemical and biophysical research communications.

[27]  G. Wogan,et al.  Mutagenesis associated with nitric oxide production in macrophages. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  U. Engelmann,et al.  Selective expression of inducible nitric oxide synthase in human prostate carcinoma , 1998, Cancer.

[29]  I. Fidler,et al.  Suppression of tumorigenicity and metastasis of human renal carcinoma cells by infection with retroviral vectors harboring the murine inducible nitric oxide synthase gene. , 1998, Human gene therapy.

[30]  C. Harris,et al.  Frequent nitric oxide synthase-2 expression in human colon adenomas: implication for tumor angiogenesis and colon cancer progression. , 1998, Cancer research.

[31]  Weiya Ma,et al.  Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[32]  N. Colburn,et al.  Inhibitors of both nuclear factor-kappaB and activator protein-1 activation block the neoplastic transformation response. , 1997, Cancer research.

[33]  P. Hainaut,et al.  Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. , 1997, Cancer research.

[34]  B. Trump,et al.  Manganese superoxide dismutase expression inhibits soft agar growth in JB6 clone41 mouse epidermal cells. , 1997, Carcinogenesis.

[35]  Richard Graham Knowles,et al.  1400W Is a Slow, Tight Binding, and Highly Selective Inhibitor of Inducible Nitric-oxide Synthase in Vitro and in Vivo* , 1997, The Journal of Biological Chemistry.

[36]  I. Fidler,et al.  Activation of nitric oxide synthase gene for inhibition of cancer metastasis , 1996, Journal of leukocyte biology.

[37]  Richard Graham Knowles,et al.  Nitric oxide synthase activity in human breast cancer. , 1995, British Journal of Cancer.

[38]  S. McCreedy,et al.  N-nitro-L-arginine and N-monomethyl-L-arginine exhibit a different pattern of inactivation toward the three nitric oxide synthases. , 1995, Archives of biochemistry and biophysics.

[39]  P Rhodes,et al.  Roles of nitric oxide in tumor growth. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  I. Fidler,et al.  Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells , 1995, The Journal of experimental medicine.

[41]  Carl Nathan,et al.  Nitric oxide synthases: Roles, tolls, and controls , 1994, Cell.

[42]  N. Colburn,et al.  A family of mitogen-activated protein kinase-related proteins interacts in vivo with activator protein-1 transcription factor. , 1994, The Journal of biological chemistry.

[43]  Richard Graham Knowles,et al.  Nitric oxide synthase activity in human gynecological cancer. , 1994, Cancer research.

[44]  R. Cooney,et al.  Inhibitors of endogenous nitrogen oxide formation block the promotion of neoplastic transformation in C3H 10T1/2 fibroblasts. , 1993, Carcinogenesis.

[45]  N. Colburn,et al.  AP1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. , 1989, Science.

[46]  N. Colburn,et al.  Four-day duration of tumor promoter exposure required to transform JB6 promotion-sensitive cells to anchorage independence. , 1988, Cancer research.

[47]  P. Chomczyński,et al.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.

[48]  N. Colburn,et al.  Role of reactive oxygen in tumor promotion: implication of superoxide anion in promotion of neoplastic transformation in JB-6 cells by TPA. , 1985, Carcinogenesis.

[49]  N. Colburn,et al.  Phorbol diester and epidermal growth factor receptors in 12-O-tetradecanoylphorbol-13-acetate-resistant and -sensitive mouse epidermal cells. , 1982, Cancer research.

[50]  N. Colburn,et al.  Tumour promoter induces anchorage independence irreversibly , 1979, Nature.

[51]  Henry Jay Forman,et al.  Redox signaling , 2004, Molecular and Cellular Biochemistry.

[52]  N. Colburn,et al.  The role of AP-1, NF-κB and ROS/NOS in skin carcinogenesis: The JB6 model is predictive , 2004, Molecular and Cellular Biochemistry.

[53]  C. Rao,et al.  Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. , 2002, Cancer research.

[54]  H. E. Marshall,et al.  Nitrosative stress-induced apoptosis through inhibition of NF-kappa B. , 2002, The Journal of biological chemistry.

[55]  C. Cooper,et al.  Nitric oxide synthases: structure, function and inhibition. , 2001, The Biochemical journal.

[56]  A. Puga,et al.  Regulation of gene expression by reactive oxygen. , 1999, Annual review of pharmacology and toxicology.

[57]  K. M. Davies,et al.  "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. , 1996, Methods in enzymology.

[58]  N. Colburn,et al.  12‐O‐tetradecanoylphorbol‐13‐acetate—induced levels of ap‐1 proteins: a 46‐kda protein immunoprecipitated by anti‐fra‐1 and induced in promotion‐resistant but not promotion‐sensitive JB6 cells , 1992, Molecular carcinogenesis.

[59]  C. Ducrocqa,et al.  Peroxynitrite : an endogenous oxidizing and nitrating agent , 2022 .